Analyst stock forecast
Karyopharm Therapeutics Inc. Forecast: $6.40 Analyst Target
KPTI has a $6.40 target, Buy rating and 5 analysts. As of 2026-08-15.
Direct answer
Karyopharm Therapeutics Inc.'s average price target is $6.40.
The target implies +216.8% from the recorded current price, and the consensus rating is Buy.
The low target implies +48.5%, the high target implies +444.6%, and the range spans 396% of the current price.
Forecast evidence checked August 15, 2026.
Get free Karyopharm Therapeutics Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.02
- Average price target
- $6.40
- High price target
- $11.00
- Low price target
- $3.00
- Low target gap
- +48.5%
- Target upside
- +216.8%
- High target gap
- +444.6%
- Target range width
- 396%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 15, 2026
- Valid through
- August 22, 2026
Explore related company data
Read the frequently asked questions.
What is Karyopharm Therapeutics Inc.'s average price target?
Karyopharm Therapeutics Inc.'s verified average price target is $6.40. The target range is $3.00 to $11.00.
How far are Karyopharm Therapeutics Inc.'s low and high targets from the recorded price?
The low target implies +48.5%, while the high target implies +444.6%.
How many analysts are included in Karyopharm Therapeutics Inc.'s consensus?
The verified consensus includes 5 analysts.
How is Karyopharm Therapeutics Inc.'s target upside or downside calculated?
The average target of $6.40 is divided by the recorded price of $2.02, then one is subtracted to produce +216.8%. This does not guarantee a future return.
When was Karyopharm Therapeutics Inc.'s analyst forecast verified?
The data was verified on 2026-08-15. The dataset is valid through 2026-08-22.